Investigates antiviral effects of human-milk-inspired peptides in cervicovaginal tissues, indicating potential as safe microbicides.
Background: Sexually transmitted infections (STIs) remain a major global health concern, with over one million new curable cases reported daily and limited long-term treatment options. Additionally, there are limited treatment options for women with bacterial vaginosis (BV), a dysbiotic condition predisposing them to STIs. Computationally designed human-milk-inspired antimicrobial peptides (AMPs) are promising candidates for novel antiviral and antibacterial therapies. This study evaluated the cervicovaginal mucosal safety and antiviral activity of three human-milk-inspired AMPs (MAT-006, UCD-MAT-001, and UCD-MAT-002) previously shown to exhibit antimicrobial activity against BV-causing pathogens. Methods: AMP cytotoxicity and inflammatory responses were assessed in relevant genital tract cell lines and cervicovaginal tissues in vitro. AMP anti-HIV-1 and anti-HSV-2 activities were characterized in female genital tract cell lines, TZM-bl cells and HEC-1-A cells, respectively, and in time-of-addition (pre-, co-, and post-HIV-1 challenge; and post-HSV-2 challenge) experiments. The impact of seminal plasma on AMPs’ activity was also evaluated. Results: At the concentrations tested, all three AMPs showed minimal cytotoxicity and no pro-inflammatory responses in cellular and ectocervical tissue explant models. In both co- and post-exposure models, all three AMPs inhibited HIV-1 and HSV-2 replication with IC50 values ranging from 0.78 to 7.72 mg/mL. MAT-006 further showed pre-exposure anti-HIV-1 activity after 6 h (IC50 = 1.07 ± 0.515 mg/mL) and 24 h (IC50 = 0.69 ± 0.152 mg/mL) of incubation. Seminal plasma did not significantly impair MAT-006 and UCD-MAT-001 antiviral activity under experimental conditions. Conclusions: These findings demonstrate the antiviral activity of human-milk-inspired AMPs against HIV-1 and HSV-2 at concentrations that are safe to the cervicovaginal mucosa in vitro, warranting further preclinical evaluation as microbicide candidates with dual antibacterial and antiviral properties.
No takes yet. Share an insight, caveat, or question.
Yousefieh et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: